Functional Genomics Screening Laboratory

Based at the Milner Therapeutics Institute (MTI) at the University of Cambridge, the Functional Genomics Screening Laboratory (FGSL) is a key component of the Initiative. The FGSL will form collaborations to explore how genes impact on complex phenotypes in development and disease, bringing together academic researchers, AstraZeneca, and the wider UK scientific community to accelerate the development of therapies and support innovation in functional genomics.

Using advanced genetic screening techniques like arrayed CRISPR to develop new insights into complex diseases, research at the lab will initially focus on non-oncology diseases such as those affecting the immune, cardiovascular, and respiratory systems, with the potential to expand into other disease areas.

As well as a research space, the laboratory will act as a collaborative hub. Access is open to researchers across the UK, offering a key resource to the genomics community by offering extended screening capacity, expertise, and technical support. The laboratory is poised to be a transformative resource for the UK’s functional genomics community, supporting future discoveries in genetic medicine and opening up new avenues for developing diagnostics and treatments, especially in under-researched areas of health.